GLP-1 receptor agonists are associated with a lower risk of dementia than DPP-4 inhibitors in dialysis patients with diabetes.

Dual therapy with metformin and GLP-1 RAs is associated with a lower risk for adiposity-related cancers and mortality than ...

GLP-1RAs and DPP-4is are associated with a higher risk for biliary disease than SGLT2is among individuals with type 2 diabetes.

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...

Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for depression risk between new GLP-1 ...

Please provide your email address to receive an email when new articles are posted on . GLP-1s reduced depression risk vs. DPP-4 inhibitors but not SGLT2 inhibitors. However, both GLP-1s and SGLT2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced risk for obesity-related ...

A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

Reflux is more common in people on GLP 1 drugs and can itself cause cough. After removing these patients, GLP 1 users had a ...

USA: A new multicenter US cohort study has identified a potential link between the use of glucagon-like peptide-1 receptor ...